Simplify Logo
Amgen

Amgen

Biotech company creating biologic medicines

Associate Director Operations Technology

Full-TimePosted on 9/15/2026
€102.3k - €138.4k/yr
Expert
Bachelor's, Master's, PhD
Dún Laoghaire, Dublin, Ireland
In Person

About the job

Requirements
  • A Doctorate degree and 6 years of Information System and/or manufacturing technology experience, or a Master’s degree and 10 years of such experience, or a Bachelor’s degree and 12 years of such experience.
  • Six years of managerial experience directly managing people and/or leadership experience leading teams, projects, programs, or directing resource allocation.
  • Expertise in automation, data integrity, network security systems, network solutions, and regulatory trends, with experience dealing with regulatory agencies.
  • Computer Science, Manufacturing Automation, or Information System educational background.
  • Biopharma and/or pharmaceutical experience.
  • Technical depth across Information Technology and Operations Technology.
  • Experience leading teams accountable for administrative process automation, manufacturing execution, building management, laboratory instruments, laboratory information management, quality management, maintenance management, regulated document management, enterprise resource planning, product lifecycle management, data collection, aggregation, analytics, visualizations, and intelligent algorithm development.
  • Ability to translate Operations’ data and advanced analytics objectives into detailed actions across laboratory, manufacturing, supply chain, quality, engineering, and Technology organizations.
  • Direct experience delivering projects using Agile/Scrum methodology and translating business requirements into product backlogs.
  • Direct working experience with enterprise systems such as Oracle, SAP, PAS|X, PLM, Veeva, and Salesforce.
  • Knowledge of system solutions in logistics, transportation, warehousing, inventory control, procurement and purchasing, accounts payable/accounting, process automation, and manufacturing execution systems within a pharmaceutical or biotech organization.
  • Experience designing and using business and computer systems in the pharmaceutical or biotech industries.
  • Experience resolving issues, designing strategies, and implementing solutions in global, multi-system environments.
  • Knowledge of Internet commerce and web-browser transaction processing solutions.
  • Experience with Electronic Data Interchange and wireless communication technologies.
  • Experience developing system migration and evolution strategies and converting them into implemented plans.
  • Demonstrated ability to coordinate business process and system issues across multiple departments and functions.
  • Experience mentoring, motivating, leading, and managing information systems groups of business systems analysts and other information technology professionals responsible for multiple systems, applications, and functional areas.
Responsibilities
  • Lead the client-facing Operations Technology department, a multidisciplinary group that plans, advances, and supports computer application solutions for the site operations function.
  • Integrate site quality and compliance management practices with the enterprise-wide computing system.
  • Develop and implement strategies for coordinating site installations of corporate-managed computing systems.
  • Create collaborative relationships with corporate and remote-site Technology groups to harmonize practices and support.
  • Hire, mentor, develop, lead, and deploy technology professionals supporting site functional areas.
  • Serve as a resource to functional areas on the appropriate and innovative use and management of information technology.
  • Support development and implementation of the site information systems strategic plan using the corporate Operations strategy.
  • Work with production management, Quality Assurance management, executive management, and support organizations to identify critical business issues and develop an Operations Technology system plan.
  • Promote cross-department forums for system-utilization training and information exchange.
  • Collaborate with Amgen Technology organizations to support effective use of technology.
  • Oversee proof-of-concept, pilot, and project execution involving leading-edge technology.
  • Develop partnerships with big-data and analytics companies to identify, assess, and recommend technology solutions.
  • Refine the site technology strategy and roadmap around reliability, efficiency, agility, and differentiation.
  • Monitor external technology changes and facilitate technology-driven innovation and competitive advantage.
  • Drive adoption of technologies and delivery of operational efficiencies.
  • Communicate the company’s technology strategy to the site operating team.
  • Assess existing and emerging technologies for application to the site Operations environment, including advanced data analytics, machine learning, artificial intelligence, Internet of Things, modeling and simulation, virtual and augmented reality, advanced vision systems, and digital twins.
  • Advance software-application, security, validated and current good manufacturing practice-compliant systems, infrastructure, cloud, data, analytics, simulation, modeling, machine learning, and artificial intelligence capabilities.
Desired Qualifications
  • Ten or more years of Information System and/or manufacturing technology experience.
  • Biopharma and/or pharmaceutical experience.
  • Adaptability, teamwork, and decisiveness in rapidly changing and growing business environments.

About the company

Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Amgen raised 2026 revenue guidance to $38.2 billion-$39.4 billion after Q2 outperformance.
  • Repatha sales jumped 37% to $953 million, driven by cardiologist and primary-care adoption.
  • MariTide now has nine ongoing and three planned Phase 3 studies across obesity.

What critics are saying

  • Prolia and XGEVA sales fell 33% in Q2 2026 as biosimilars hit.
  • FDA proposed withdrawing TAVNEOS in April 2026, threatening a marketed rare-disease franchise.
  • If MariTide misses 2027 endpoints, Amgen loses its next obesity growth pillar.

What makes Amgen unique

  • Amgen's six growth drivers produced nearly 70% of Q2 2026 product sales.
  • IMDELLTRA sales rose 115% in Q2 2026, validating Amgen's oncology engine.
  • Hyderabad's 2027 Science and Innovation Center expands Amgen's seven-lab global R&D network.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Yahoo Finance
Sep 11th, 2026
Revolution Medicines' first pancreatic cancer therapy approval challenges Amgen's biotech dominance

Revolution Medicines received FDA approval for daraxonrasib, the first targeted therapy for metastatic pancreatic cancer, after clinical data showed it reduced death risk by more than half. The company is clinical-stage with no current revenue and posted a $1.1 billion net loss in FY 2025. Amgen reported FY 2025 revenue of $36.7 billion, up 9.9% year-over-year, with net income of $7.7 billion and a 21% net margin. Free cash flow reached $8.1 billion. The company carries a debt-to-equity ratio of 6.3x. Revolution Medicines maintains a 0.1x debt-to-equity ratio and 9.5x current ratio but recorded negative free cash flow of $913.7 million. The company's pipeline targets RAS-driven tumours including lung cancer. A partnership with Royalty Pharma provides funding for development. Both companies face distinct risks: Amgen confronts pricing pressures and biosimilar competition, whilst Revolution Medicines carries clinical trial failure risks and competes against larger pharmaceutical firms.

Yahoo Finance
Sep 11th, 2026
Amgen vs CRISPR Therapeutics: Which healthcare stock offers better value in 2026?

Amgen reported revenue of $36.7 billion in FY 2025, up 9.9% year-over-year, with net income of $7.7 billion and a 21% net margin. The biotech giant maintains a debt-to-equity ratio of 6.3x and generated $8.1 billion in free cash flow. CRISPR Therapeutics, meanwhile, saw revenue fall 90% to $3.5 million in FY 2025, posting a net loss of $581.6 million. The gene-editing firm burns $345.9 million in cash but holds a strong current ratio of 13.3x. Its CASGEVY therapy for sickle cell disease has gained approval in the US, UK, and EU, with Vertex handling commercialisation under a 60-40 revenue split. Amgen faces pricing pressure from the Inflation Reduction Act and biosimilar competition. CRISPR Therapeutics carries clinical execution risk and ongoing intellectual property disputes.

Yahoo Finance
Sep 11th, 2026
Amgen and AstraZeneca lung cancer drug combo meets survival goal in phase III study

Amgen and AstraZeneca announced positive results from the phase III DeLLphi-305 study evaluating Amgen's Imdelltra (tarlatamab) combined with AstraZeneca's Imfinzi (durvalumab) as first-line maintenance treatment for extensive-stage small-cell lung cancer (ES-SCLC). The study met its primary endpoint of overall survival and key secondary endpoint of progression-free survival, with no new safety concerns identified. ES-SCLC affects approximately 195,000 people globally. If approved, the combination would compete with Jazz Pharmaceuticals' Zepzelca plus Roche's Tecentriq, which received FDA approval in October 2025. Imdelltra, approved in 2024 for ES-SCLC progression after platinum-based chemotherapy, generated $546 million in global sales during the first half of 2026, up from $215 million in the prior-year period.

Yahoo Finance
Sep 10th, 2026
Amgen vs. Moderna: Which healthcare stock is a better buy in 2026?

Amgen reported FY 2025 revenue of $36.7 billion, up 9.9% year-over-year, with net income of $7.7 billion and a 21% net margin. The biotech serves 17 million patients globally with treatments for heart disease, obesity, and cancer. However, three distributors—McKesson, Cencora, and Cardinal Health—accounted for 77% of gross revenues, creating concentration risk. The company's debt-to-equity ratio stood at 6.3x. Moderna posted FY 2025 revenue of $1.9 billion, down 39.2% as pandemic-related vaccine demand declined. The mRNA specialist reported a net loss of $2.8 billion, resulting in a negative 145.2% net margin due to high research and development costs. The company is pivoting its mRNA platform toward infectious diseases, cancer, and rare conditions whilst expanding through partnerships like its collaboration with Merck.

Yahoo Finance
Sep 10th, 2026
Amgen trades at 17x 2026 earnings, but forecast margin expansion assumes MariTide success

Amgen trades at $393 per share, representing a trailing multiple of 23.3 times adjusted earnings. The biotech faces declining sales from Prolia and XGEVA, down 33% year-over-year to $1.1 billion in Q2 2026, due to biosimilar competition. Six key growth medicines grew 26% year-over-year, accounting for nearly 70% of Q2 product sales. Analysts forecast the forward multiple at 17.0 times for fiscal 2026 and 16.1 times for 2027. However, consensus assumes expanding profit margins whilst Amgen increases spending. Non-GAAP research spending is set to grow in high single digits for 2026, funding nine Phase III trials for MariTide, its obesity treatment candidate. Management warned of meaningful operating expense increases in Q3 2026. The valuation depends on margin expansion materialising during this investment phase.